688356 Jenkem Technology
- 57.80
- +1.09+1.92%
Jenkem Technology News
Express News | Next week, the unlocking ratio of 10 stocks will exceed 50%.
Jenkem Technology's Unit Completes Enrollment of First Subject for Polyethylene Glycol Irinotecan for Injection Trial
Jenkem technology (688356.SH): The first subject enrolled in the Phase II clinical trial of Polyethylene Glycol Ilibycin for the treatment of triple-negative breast cancer with brain metastases completed.
Gelonghui November 12th | Jenkem Technology (688356.SH) announced that its independently developed injection polyethylene glycol Iletikan (pharmaceutical code: JK1201I) for the treatment of triple-negative breast cancer with brain metastasis has completed the first subject enrollment in the phase II clinical trial "JK1201I treatment of triple-negative breast cancer with brain metastasis Phase II clinical study" recently.
2024 THIRD QUARTER REPORT (CORRECTED)
Corrections to the 2024 Third Quarter Report
Jiankai Technology: Third quarter report 2024
Third Quarter Report 2024
Jenkem Technology (688356.SH): The net income in the first three quarters was 32.6537 million yuan, a decrease of 67.50% year-on-year.
Grain headlines October 30th | Jenkem Technology (688356.SH) announced that in the first three quarters of 2024, it achieved revenue of 0.186 billion yuan, a 23.97% decrease year-on-year; the net income attributable to shareholders of the listed company was 32.6537 million yuan, a 67.50% decrease year-on-year, with a basic earnings per share of 0.54 yuan.
Jenkem Technology Enrolls First Subject for Phase III Trial of Lung Cancer Drug; Shares Jump 13%
Express News | Jenkem Technology: Wholly-owned subsidiary's Phase III clinical trial of injectable polyethylene glycol iloprost completed the first subject enrollment.
Express News | Jenkem Technology: The first subject was enrolled in Phase III clinical trial of JK1201I.
Express News | Star Market closing review: SSE Science and Technology Innovation Board 50 Index fell by 1.33%. Biopharmaceutical and photovoltaic sectors are feeling low.
Jenkem Technology (688356.SH): The safety of JK1201I second-line treatment for patients with extensive-stage small cell lung cancer is good and patients can tolerate it.
Jenkem Technology (688356.SH) announced recently that its wholly-owned subsidiary tianjin Jenkem Technology Co., Ltd...
jenkem technology (688356.SH): The phase II study of the safety, tolerability, and preliminary efficacy of polyethylene glycol irinetecan in the second-line monotherapy treatment of small cell lung cancer was published in a journal.
On September 4, Geelong announced that the safety, tolerability, and preliminary efficacy of JK1201I, a polyethylene glycol (PEG) -based irisetamcin injection (drug code: JK1201I) developed independently by its wholly-owned subsidiary, Tianjin Jenkem Technology Co., Ltd., for the second-line monotherapy of small cell lung cancer, was published in the international academic journal 'Cancer Medicine' (impact factor 4.0). JK1201I is a small molecule long-acting class 1 innovative anticancer drug developed by the company, which uses polyethylene glycol to formulate irisetamcin.
Jenkem Technology (688356.SH): has repurchased 0.244% of the shares.
Grainstream September 2nd | Jenkem Technology (688356.SH) announced that as of August 31, 2024, the company has repurchased a cumulative total of 0.147914 million shares through the Shanghai Stock Exchange trading system in a centralized bidding trading method. The proportion of company's total share capital is 0.2440%. The highest price for repurchase transactions is 75.05 yuan per share, the lowest price is 62.85 yuan per share, and the total amount paid is RMB 10,500,337.30 (excluding stamp duty, trading commissions, and other transaction costs).
2024 Semi-Annual Report
2024 Semi-Annual Report Summary
Jenkem Technology (688356.SH) released its semi-annual financial performance with a net income of 27.9448 million yuan, a decrease of 59.06% year-on-year.
Jenkem Technology (688356.SH) disclosed its 2024 interim report, with the company achieving revenue of 1...
Jenkem Technology (688356.SH): Net income in the first half of the year was 27.9448 million yuan, a year-on-year decrease of 59.06%.
Jenkem Technology (688356.SH) announced its semi-annual report for 2024, with revenue of 0.129 billion yuan, a 24.99% year-on-year decrease; net income attributable to shareholders of the listed company of 27.9448 million yuan, a 59.06% year-on-year decrease; net income attributable to shareholders of the listed company after deducting non-recurring gains and losses of 21.7155 million yuan, a 67.48% year-on-year decrease; basic earnings per share of 0.46 yuan.
Express News | Jenkem technology: the indication for injection of polyethylene glycol irinotecan for the treatment of glioblastoma is still in the phase II enrollment stage.
Analysis
Price Target
No Data
No Data